The use of prostatilen in treating patients with chronic prostatitis
Observational study · 1991
- What was studied
- 307 men with chronic prostatitis
- Main finding
- An uncontrolled 307-person chronic-prostatitis series reported symptom disappearance or attenuation in 96.7% after Prostatilen.
Disappearance or attenuation; uncontrolled composite clinical response
Reported findings and study design
An uncontrolled 307-person chronic-prostatitis series reported symptom disappearance or attenuation in 96.7% after Prostatilen.
307 patients aged 18–74; disease duration 4 months–36 years; assessments at treatment completion and 4–6 months later.
Dose, route and schedule
Prostatilen: 5–10 mg intramuscularly once daily for five to ten days.
Protocol source ↗ · Indexed publication abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Reported symptom response | 96.7% | Disappearance or attenuation; uncontrolled composite clinical response |
| Onset of response | After 2–3 injections; greatest reported response after 5–6 | Descriptive clinical observation |
| Studied regimen | 5–10 mg intramuscularly daily for 5–10 days | |
| Participants | 307 |
The abstract does not give a placebo response, a validated symptom-score change or separate response rates at each follow-up. Its claim of no side effects is not a systematic incidence estimate.
Source for these results ↗ · Reviewed 2026-11-01
Study limitations and source details
Study limitations
- The abstract does not establish a randomized concurrent control.
- Reported tolerability cannot establish long-term safety; findings do not apply to Prostamax.
Source details
Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Sources checked
Citation
Tkachuk VN, Gorbachev AG, Khavinson VKh. The use of prostatilen in treating patients with chronic prostatitis Urol Nefrol (Mosk) (6):40-43. PMID 1823682